2022 World Conference on Lung Cancer (ePosters)-EP16.02-024. Plasma ctDNA Organ-Specific Genomic Patterns and Origination Analysis in Advanced Non-Small Cell Lung Cancer

EP16.02-024. Plasma ctDNA Organ-Specific Genomic Patterns and Origination Analysis in Advanced Non-Small Cell Lung Cancer

Back to course

Pdf Summary

The study aimed to investigate the patterns of circulating tumor DNA (ctDNA) mutations and their origins in patients with advanced non-small cell lung cancer (NSCLC). The researchers analyzed plasma samples from 23 patients with advanced NSCLC and tissue samples from 23 primary tumors and 36 metastases. <br /><br />The results showed that patients with locoregional metastases had more mutations detected in plasma that were specific to the metastatic lesions (MT-private mutations), while patients with distant metastases showed more mutations specific to the primary tumors (PT-private mutations) in plasma. In tissue samples, the majority of mutations (78.9%) were MT-private, while 15.1% were PT-private and 6.0% were shared by primaries and metastases. <br /><br />In patients with distant metastases to the adrenal gland or brain, a higher proportion of PT-private mutations were detected in plasma compared to MT-private and shared mutations. On the other hand, patients with locoregional metastases to the pleura or lymph nodes showed a preference for MT-private mutations in plasma. <br /><br />EGFR mutations were the most prevalent clonal mutations detected in tissues, with almost half of them also detected in plasma. The presence of NOTCH2 mutations in plasma was significantly associated with poor prognosis in patients with pleura metastases. <br /><br />Overall, this study highlights the organ-specific genomic patterns of ctDNA mutations in advanced NSCLC and suggests that analyzing the origin of these mutations may help interpret their clinical significance.

Asset Subtitle

Rui Fu

Meta Tag

Speaker Rui Fu

Topic Tumour Biology and Biomarkers - Minimally Invasive Biomarkers

Keywords

circulating tumor DNA

ctDNA mutations

non-small cell lung cancer

plasma samples

tissue samples

metastases

MT-private mutations

PT-private mutations

EGFR mutations

clinical significance